{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib&page=2",
    "query": {
      "intervention": "ruxolitinib",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 291,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T22:24:47.908Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07352566",
      "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "In situ cutaneous microdevice",
          "type": "DEVICE"
        },
        {
          "name": "Triamcinolone",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Calcipotriene",
          "type": "DRUG"
        },
        {
          "name": "Tapinarof",
          "type": "DRUG"
        },
        {
          "name": "Crisaborole",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab",
          "type": "DRUG"
        },
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Risankizumab",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Chloroquine",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Deucravacitinib",
          "type": "DRUG"
        },
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Tralokinumab",
          "type": "DRUG"
        },
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Tildrakizumab",
          "type": "DRUG"
        },
        {
          "name": "Baractinib",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        },
        {
          "name": "Nemolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        },
        {
          "name": "Roflumilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2026-08-01",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07352566"
    },
    {
      "nct_id": "NCT07357441",
      "title": "A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 355,
      "start_date": "2022-04-07",
      "completion_date": "2023-06-28",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07357441"
    },
    {
      "nct_id": "NCT07424222",
      "title": "Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 16,
      "start_date": "2026-07-15",
      "completion_date": "2029-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07424222"
    },
    {
      "nct_id": "NCT05635838",
      "title": "Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2022-12-07",
      "completion_date": "2024-03-14",
      "has_results": true,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05635838"
    },
    {
      "nct_id": "NCT02436135",
      "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2015-06-05",
      "completion_date": "2017-11-20",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02436135"
    },
    {
      "nct_id": "NCT04562389",
      "title": "Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 353,
      "start_date": "2021-03-11",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Duarte, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04562389"
    },
    {
      "nct_id": "NCT04921969",
      "title": "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 330,
      "start_date": "2021-07-19",
      "completion_date": "2024-04-08",
      "has_results": true,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04921969"
    },
    {
      "nct_id": "NCT04551066",
      "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelofibrosis",
        "Primary Myelofibrosis",
        "Post Essential Thrombocythemia Myelofibrosis",
        "Post Polycythemia Vera Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "parsaclisib",
          "type": "DRUG"
        },
        {
          "name": "ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2021-05-24",
      "completion_date": "2024-11-25",
      "has_results": true,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 36,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04551066"
    },
    {
      "nct_id": "NCT04676529",
      "title": "Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis",
        "Primary Myelofibrosis (PMF)",
        "Post- Essential Thrombocythemia Myelofibrosis",
        "Post Polycythemia Vera Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "PXS-5505",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syntara",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2021-02-18",
      "completion_date": "2025-07-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676529"
    },
    {
      "nct_id": "NCT02226172",
      "title": "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Glasdegib (PF-04449913)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2014-10-06",
      "completion_date": "2018-01-31",
      "has_results": true,
      "last_update_posted_date": "2019-01-17",
      "last_synced_at": "2026-10-16T22:24:47.908Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02226172"
    }
  ]
}